What is the optimal duration for a ROAT? The experience of the French Dermatology and Allergology group (DAG).


Journal

Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950

Informations de publication

Date de publication:
Aug 2022
Historique:
revised: 22 03 2022
received: 05 10 2021
accepted: 25 03 2022
pubmed: 7 4 2022
medline: 19 7 2022
entrez: 6 4 2022
Statut: ppublish

Résumé

The repeated open application test (ROAT) is an adjuvant investigation measure to patch testing in the diagnosis of allergic contact dermatitis. ESCD recommends a 15 days duration but its overall duration varies according to publications and patients hardly adhere to prolonged ROAT duration beyond 1 week. The Dermatology and Allergy Group of the French Society of Dermatology performed a prospective study with the aim of determining the best duration for the ROAT. A total of 328 ROAT results were collected for topical products, including cosmetics (60%) and topical medications (31.1%). Fifty-nine (18%) ROATs were positive, and 16 (5%) were doubtful. All the positive ROATs occurred within 10 days, with a median time to positivity of 3 days. According to our results, a minimum duration of 10 days is necessary to achieve a positive ROAT to a topical product.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
The repeated open application test (ROAT) is an adjuvant investigation measure to patch testing in the diagnosis of allergic contact dermatitis. ESCD recommends a 15 days duration but its overall duration varies according to publications and patients hardly adhere to prolonged ROAT duration beyond 1 week.
MATERIALS AND METHODS METHODS
The Dermatology and Allergy Group of the French Society of Dermatology performed a prospective study with the aim of determining the best duration for the ROAT.
RESULTS RESULTS
A total of 328 ROAT results were collected for topical products, including cosmetics (60%) and topical medications (31.1%). Fifty-nine (18%) ROATs were positive, and 16 (5%) were doubtful. All the positive ROATs occurred within 10 days, with a median time to positivity of 3 days.
CONCLUSION CONCLUSIONS
According to our results, a minimum duration of 10 days is necessary to achieve a positive ROAT to a topical product.

Identifiants

pubmed: 35383393
doi: 10.1111/cod.14118
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

170-175

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Hannuksela M, Salo H. The repeated application test (ROAT). Contact Dermatitis. 1986;14(4):221-227.
Brown GE, Botto N, Butler DC, Murase JE. Clinical utilization of repeated open application test among American contact dermatitis society members. Dermatitis. 2015;26(5):224-228.
Bruze M, Engfeldt M, Ofenloch R, et al. Validation of a questionnaire algorithm based on repeated open application testing with the constituents of fragrance mix I. Br J Dermatol. 2020;182(4):955-964.
Nakada T, Hostynek JJ, Maibach HI. Use tests: ROAT (repeated open application test)/PUT (provocative use test): an overview. Contact Dermatitis. 2000;43(1):1-3.
Hannuksela A, Ninimaki A, Hannuksela M. Size of the test area does not affect the result of repeated open application test. Contact Dermatitis. 1993;28(5):299-230.
Johansen JD, Bruze M, Andersen KE, et al. The repeated open application test: suggestions for a scale or evaluation. Contact Dermatitis. 1998;39(2):95-96.
Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing-recommendations on best practice. Contact Dermatitis. 2015;73(4):195-221.
Grey KR, Warshaw EM. Allergic contact dermatitis to ophthalmic medications: relevant allergens and alternative testing methods. Dermatitis. 2016;27(6):333-347.
Assier H, Tetart F, Avenel-Audran M, et al. Is a specific eyelid patch test series useful? Results of a French prospective study. Contact Dermatitis. 2018;79(3):157-161.

Auteurs

Emmanuelle Amsler (E)

Service de dermatologie et allergologie, Hôpital Tenon, Paris, France.

Haudrey Assier (H)

Service de Dermatologie, Hôpital Henri Mondor, Créteil, France.

Angèle Soria (A)

Service de dermatologie et allergologie, Hôpital Tenon, Paris, France.

Corina Bara (C)

Service de dermatologie, Centre Hospitalier Le Mans, Le Mans, France.

Marie Christine Ferrier le Bouëdec (MC)

Service de dermatologie, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.

Annick Barbaud (A)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP. Sorbonne Université, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France.

Brigitte Milpied (B)

Service de Dermatologie, Hôpital St André, Bordeaux, France.

Françoise Giordano-Labadie (F)

Service de Dermatologie, Hôpital Larrey, CHU Toulouse, Toulouse, France.

Justine Pasteur (J)

Service de dermatologie, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.

Antoine Badaoui (A)

Service de dermatologie, Hôpital d'Instruction des Armées Bégin, St Mandé, France.

Aude Valois (A)

Service de Dermatologie, Hôpital d'Instruction des Armées Sainte Anne 2 boulevard Sainte Anne, Toulon Cedex, France.

Florence Castelain (F)

Service de Dermatologie, CHU Besançon, Besançon, France.

Flore Kurihara (F)

Service de dermatologie et allergologie, Hôpital Tenon, Paris, France.

Julie Castagna (J)

Service de dermatologie et allergologie, Hôpital Tenon, Paris, France.

Claire Boulard (C)

Service de dermatologie, Groupe hospitalier du Havre, Le Havre, France.

Claire Bernier (C)

Service de dermatologie, CHU Hôtel Dieu, Nantes, France.

Camille Leleu (C)

Service de Dermatologie, CHU François Mitterrand, Dijon, France.

Pierre Marcant (P)

Service de dermatologie, Centre hospitalier universitaire de Lille, Lille, France.

Marie Noelle Crépy (MN)

Department of Occupational and Environmental Diseases, University Hospital of Centre of Paris, Hotel-Dieu Hospital, Paris, France.
Department of Dermatology, University Hospital of Centre of Paris, Cochin Hospital, Paris, France.

Florence Tetart (F)

Centre Erik Satie Allergologie, Rouen University Hospital, Rouen, France.

Nadia Raison-Peyron (N)

Service de Dermatologie, Hôpital Saint Eloi, CHU Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH